KindlyMD (NASDAQ:NAKA) CEO David Bailey Buys 32,134 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 32,134 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was bought at an average price of $5.59 per share, with a total value of $179,629.06. Following the purchase, the chief executive officer directly owned 32,134 shares in the company, valued at approximately $179,629.06. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

KindlyMD Stock Performance

Shares of KindlyMD stock opened at $7.06 on Friday. The business has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $7.24. KindlyMD, Inc. has a one year low of $3.33 and a one year high of $422.40. The company has a market cap of $126.34 million, a PE ratio of -0.20 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA) last issued its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The firm had revenue of $35.87 million during the quarter. On average, sell-side analysts predict that KindlyMD, Inc. will post -11.31 earnings per share for the current fiscal year.

Key Headlines Impacting KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Hedge Funds Weigh In On KindlyMD

Several hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in shares of KindlyMD in the 4th quarter valued at $151,000. J. Derek Lewis & Associates Inc. acquired a new stake in KindlyMD during the 4th quarter worth $167,000. Truist Financial Corp acquired a new stake in KindlyMD during the 4th quarter worth $176,000. Waddell & Associates LLC purchased a new stake in KindlyMD in the fourth quarter valued at $201,000. Finally, Invesco Ltd. purchased a new stake in KindlyMD in the fourth quarter valued at $211,000.

Analyst Upgrades and Downgrades

NAKA has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Wall Street Zen raised KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Finally, TD Cowen raised their price target on KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, KindlyMD has a consensus rating of “Hold” and an average target price of $22.33.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.